Results 81 to 90 of about 49,053 (243)

Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta‐analysis

HIV Medicine, EarlyView.
Abstract Introduction Antiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non‐communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood.
Melani Ratih Mahanani, Myo Chit, Sophie Mohr, Elisenda Cama i Gibernau, Svetlana Hetjens, Volker Winkler, Hans‐Michael Steffen, Florian Neuhann   +7 more
wiley   +1 more source

Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity

, 2012
An attenuation of the HIV-1 replication capacity (RC) has been observed for immune-mediated escape mutations in Gag restricted by protective HLA alleles.
Olvera, A., Markle, T.J., Cheung, P.K., John, M., Brumme, Z.L., Brumme, C.J., Carlson, J.M., Kelleher, A.D., Markowitz, M., Frahm, N., McGovern, R., Harrigan, P.R., Brander, C., Heckerman, D., Sanchez, J., Walker, B.D., Chopera, D.R., Sela, J., Le, A.Q., Jessen, H., Martin, E., Rosenberg, E., Brockman, M.A., Mallal, S.   +23 more
core  

HIV drug resistance and treatment success in the Republic of Congo: Implications for optimized treatment

HIV Medicine, EarlyView.
Abstract Objectives Increasing rates of HIV‐1 drug resistance (HIVDR) threaten the effectiveness of antiretroviral therapy (ART) programmes in sub‐Saharan Africa, particularly among children, adolescents and young adults, who face limited treatment options.
Dominic Rauschning, Arcy Marcelin Elenga Ike, Johanna Holterhoff, Amira Stockinger, Darrel Ornelle Elion Assiana, Claujens Chastel Mfoutou Mapanguy, Freisnel Hermeland Mouzinga, Carola Horn, Isabelle Suarez, Ferdinand Heyn, Diane Alexia Fila, Hubert Banguissa, Fabien Roch Niama, Donatien Moukassa, Eva Heger, Francine Ntoumi, Clara Lehmann   +16 more
wiley   +1 more source

Fitness Impaired Drug Resistant HIV-1 Is Not Compromised in Cell-to-Cell Transmission or Establishment of and Reactivation from Latency

Viruses, 2014
Both the presence of latently infected cells and cell-to-cell viral transmission are means whereby HIV can partially evade the inhibitory activities of antiretroviral drugs.
Sophie M. Bastarache, Thibault Mesplède, Daniel A. Donahue, Richard D. Sloan, Mark A. Wainberg   +4 more
doaj   +1 more source

Structural Comparison of Diverse HIV-1 Subtypes using Molecular Modelling and Docking Analyses of Integrase Inhibitors

Viruses, 2020
The process of viral integration into the host genome is an essential step of the HIV-1 life cycle. The viral integrase (IN) enzyme catalyzes integration. IN is an ideal therapeutic enzyme targeted by several drugs; raltegravir (RAL), elvitegravir (EVG),
Darren Isaacs, Sello Given Mikasi, Adetayo Emmanuel Obasa, George Mondinde Ikomey, Sergey Shityakov, Ruben Cloete, Graeme Brendon Jacobs   +6 more
doaj   +1 more source

Prior PrEP use and discontinuation in individuals newly diagnosed with HIV

HIV Medicine, EarlyView.
Abstract Background In settings with high uptake of HIV pre‐exposure prophylaxis (PrEP), an increasing proportion of individuals newly diagnosed with HIV report prior PrEP exposure. Understanding patterns of PrEP use, discontinuation and adherence in such settings is essential to inform future HIV prevention strategies.
Rohan Saini, Sarah Fidler, Marta Boffito, Vicky Tittle, Nicolo Girometti, Gary Whitlock, on behalf of the Dean Street Collaborative Group, Keerti Gedela, Franki Lander, Alan McOwan, Diarmuid Nugent, Sheel Patel, Sashini Payagala, Tara Suchak, Vicky Tittle, Gary Whitlock   +15 more
wiley   +1 more source

Raltegravir: first in class HIV integrase inhibitor

, 2008
Zelalem Temesgen1, Dawd S Siraj21Mayo Clinic, Rochester, MN, USA; 2East Carolina University Greenville, NC, USAAbstract: On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus ...
Dawd S Siraj, Zelalem Temesgen
core  

Structural Insights on Retroviral DNA Integration: Learning from Foamy Viruses

Viruses, 2019
Foamy viruses (FV) are retroviruses belonging to the Spumaretrovirinae subfamily. They are non-pathogenic viruses endemic in several mammalian hosts like non-human primates, felines, bovines, and equines.
Ga-Eun Lee, Eric Mauro, Vincent Parissi, Cha-Gyun Shin, Paul Lesbats   +4 more
doaj   +1 more source

Screening for bone health in older people with HIV: Uptake and outcomes from a large UK outpatient HIV service

HIV Medicine, EarlyView.
Abstract Objectives Bone health is negatively affected in people with HIV, and the risks of osteoporosis and fragility fractures are increased. The objective of this study was to describe the characteristics of those accessing bone health screening and identify factors associated with osteoporosis.
Rhys Nicholas, Kate Alford, Colin Fitzpatrick, Jaime Vera   +3 more
wiley   +1 more source

Long‐Acting Cabotegravir/Rilpivirine Reduces Immune‐Activation and ‐Senescence in People With HIV With CMV Co‐Infection

Immunology, EarlyView.
This study investigates the impact of switching to long‐acting (LA) injectable cabotegravir and rilpivirine (CAB/RPV‐LA) on immune‐activation and ‐senescence in people with HIV (PWH). Thirty‐seven PWH switching to CAB/RPV‐LA and nine continuing oral ART were analysed over 72 weeks. LA therapy led to significant reductions in activation T and senescence
Mariasilvia Guardiani, Eeva Tortellini, Anna Carraro, Maria Antonella Zingaropoli, Lorenzo Ansaldo, Alessandra Grimaldi, Serena Vita, Federica Dominelli, Fabio Mengoni, Caterina Pasquazzi, Ombretta Turriziani, Maria Rosa Ciardi, Vincenzo Vullo, Claudio Maria Mastroianni, Raffaella Marocco, Cosmo Del Borgo, Miriam Lichtner   +16 more
wiley   +1 more source